Absence of the JAK2 mutation V617F in CD34+ hematopoietic stem and progenitor cells from patients with BCR-ABL-positive CML in chronic phase and blast crisis-Reference-Cited by-同舟云学术

Absence of the JAK2 mutation V617F in CD34+ hematopoietic stem and progenitor cells from patients with BCR-ABL-positive CML in chronic phase and blast crisis

Published:2006-10 Issue:10 Volume:30 Page:1323-1324
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Kronenwett Ralf,Gräf Thorsten,Neumann Frank,Pechtel Sabrina,Steidl Ulrich,Diaz-Blanco Elena,Haas Rainer

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference10 articles.

1. A unique activating mutation in JAK2 (V617F) is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseases;Vainchenker;Hematology (Am Soc Hematol Educ Program),2005

2. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders;Jones;Blood,2005

3. JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia;Jelinek;Blood,2005

4. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia;Levine;Blood,2005

5. The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders;Scott;Blood,2005

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emergence of BCR-ABL1 Chronic Myeloid Leukemia in a JAK2-V617F Polycythemia Vera;Journal of Hematology;2020

2. Simultaneous occurrence of the JAK2V617F mutation and BCR-ABL gene rearrangement in patients with chronic myeloproliferative disorders;Leukemia Research;2008-06

3. Analysis of the exon 12 and 14 mutations of the JAK2 gene in Philadelphia chromosome-positive leukemia;Leukemia;2007-09-13

4. Marrow fibrosis and its relevance during imatinib treatment of chronic myeloid leukemia;Leukemia;2007-09-06

5. Reply to ‘Myeloproliferative disorders with coexisting BCR-ABL translocation and JAK2V617F mutation’ by Dr Ronald S Go;Leukemia;2007-06-28